Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States

被引：0

作者：

Penn, Courtney Alexis ^{[1
]}

Wong, Melissa Spring ^{[2
]}

Walsh, Christine ^{[2
]}

机构：

[1] Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA

[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

来源：

GYNECOLOGIC ONCOLOGY | 2020年 / 159卷 / 02期

关键词：

D O I：

10.1016/j.ygyno.2020.07.050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E14 / E14

页数：1

共 50 条

[11] Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States [J].

Qu, T. ;

Zhong, Y. ;

Zhang, S. ;

Meng, Y. ;

Joo, S. ;

Shah, S. .

ANNALS OF ONCOLOGY, 2021, 32 :S1059-S1060

[12] COST-EFFECTIVENESS OF EFAVIRENZ VERSUS RILPIVIRINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES [J].

Bonafede, M. ;

Juday, T. ;

Lenhart, G. ;

Pan, K. ;

Hebden, T. ;

Correll, T. .

VALUE IN HEALTH, 2012, 15 (04) :A241-A241

[13] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer [J].

Attard, C. L. ;

Brown, S. ;

Alloul, K. ;

Moore, M. J. .

CURRENT ONCOLOGY, 2014, 21 (01) :E41-E51

[14] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer [J].

Franken, M. D. ;

van Rooijen, E. M. ;

May, A. M. ;

Koffijberg, H. ;

van Tinteren, H. ;

Mol, L. ;

ten Tije, A. J. ;

Creemers, G. J. ;

van der Velden, A. M. T. ;

Tanis, B. C. ;

Groot, C. A. Uyl-de ;

Punt, C. J. A. ;

Koopman, M. ;

van Oijen, M. G. H. .

EUROPEAN JOURNAL OF CANCER, 2017, 75 :204-212

[15] COST-EFFECTIVENESS OF OLAPARIB PLUS BEVACIZUMAB FIRST-LINE MAINTENANCE IN OVARIAN CANCER ALONGSIDE THE PAOLA-1 TRIAL [J].

Perrier, L. ;

Zarca, K. ;

Cadet, T. ;

Morelle, M. ;

Cropet, C. ;

Burges, A. ;

Cecere, S. C. ;

Palacio, I ;

Polterauer, S. ;

Yoshida, H. ;

Vuylsteke, P. ;

Colombo, N. ;

Nottrup, T. J. ;

Abdeddaim, C. ;

El-Balat, A. ;

Cinieri, S. ;

Herrero, A. ;

Kaminski, M. C. ;

Pujade-Lauraine, E. ;

Durand-Zaleski, I ;

Ray-Coquard, I .

VALUE IN HEALTH, 2023, 26 (12) :S61-S62

[16] COST-EFFECTIVENESS OF EFAVIRENZ COMPARED WITH GENERIC NEVIRAPINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES [J].

Bonafede, M. M. ;

Juday, T. ;

Farr, A. ;

Lenhart, G. M. ;

Hebden, T. ;

Correll, T. .

VALUE IN HEALTH, 2013, 16 (03) :A92-A92

[17] COST-EFFECTIVENESS OF TREMELIMUMAB PLUS DURVALUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE UNITED STATES [J].

Xiong, X. ;

Guo, J. J. .

VALUE IN HEALTH, 2024, 27 (06) :S152-S152

[18] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. [J].

Attard, Cheryl L. ;

Brown, Stephen ;

Alloul, Karine ;

Moore, Malcolm J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)

[19] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN [J].

Moreno, V ;

Martinez-Amores, B. ;

Barriuso, J. ;

Mezquita, L. ;

Ibanez de Caceres, I. ;

Ayuso, A. ;

Pena, J. M. ;

Perona, R. ;

Grande, E. ;

Belda-Iniesta, C. .

VALUE IN HEALTH, 2012, 15 (07) :A421-A422

[20] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain [J].

Moreno, Victor ;

Martinez-Amores, Brezo ;

Barriuso, Jorge ;

Mezquita, Laura ;

Ibanez de Caceres, Inmaculada ;

Ayuso Sacido, Angel ;

Maria Pena, Jose ;

Perona, Rosario ;

Belda-Iniesta, Cristobal .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →